Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05097222
Other study ID # BioFlex_PCS_001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 27, 2022
Est. completion date December 13, 2023

Study information

Verified date May 2024
Source HealthTech Connex Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Photobiomodulation therapy (PBMT) uses light to influence the mitochondria of cells. PBMT of the brain enhances the metabolic capacity of neurons and stimulates anti-inflammatory, anti-apoptotic, and antioxidant responses, as well as neurogenesis and synaptogenesis. Its therapeutic role in disorders such as dementia and Parkinson's disease, as well as to treat stroke, brain trauma, and depression has gained increasing interest. BioFlex is a form of PBMT consisting of light-emitting diodes (LEDs) and laser diodes. BioFlex utilizes red and near infrared light which penetrates tissues up to a certain tissue depth and studies have shown stimulates tissue growth and repair at the cellular level. PBMT has been proven useful for the treatment of soft tissue pain. Several studies have shown benefit in using PBMT in the treatment of certain neurological conditions, including chronic, mild traumatic brain injury (mTBI). The purpose of this exploratory investigation, therefore, is to examine efficacy of BioFlex laser therapy on measures of brain function in patients suffering from PCS after mild-moderate, closed-head, traumatic brain injury cases.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date December 13, 2023
Est. primary completion date December 13, 2023
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: 1. Male or female, at least 19 years of age or older 2. Diagnosis of persistent post-concussional syndrome after =3 months of traumatic brain injury, based on the ICD-10 criteria. This diagnosis should be given to the patient from a clinical practitioner. ICD-10 clinical criteria require a history of TBI and the presence of three or more of the following eight symptoms: 1) headache, 2) dizziness, 3) fatigue, 4) irritability, 5) insomnia, 6) concentration or 7) memory difficulty, and 8) intolerance of stress, emotion, or alcohol. 3. Current pharmacologic management can remain stable throughout the protocol. 4. Fluent in English 5. Able to understand the informed consent form, study procedures and willing to participate in study. Exclusion Criteria: 1. Malignant skin carcinoma within the treatment area (neck and cranium) 2. Intake of photosensitizing medication. 3. Prior history of PBMT therapy 4. Current diagnosis of severe anxiety (or score of =15 on the GAD-7), severe depression (or score of =20 on the PHQ-9), schizophrenia or bipolar disorder 5. History of other major neurological disorder (brain cancer, dementia, multiple sclerosis, stroke) 6. Diagnosed epilepsy or history of seizures not effectively controlled by medications 7. Exposed to an investigational drug or device 30 days prior to starting the study, or concurrent use of an investigational drug or device while enrolled in the study 8. Pregnant, suspected to be pregnant or planning to become pregnant during the study 9. Contraindicated for the NeuroCatch® Platform 2, including: 9.1. Requires the use of hearing aids or a cochlear implant 9.2. Diagnosed with tinnitus that is currently active 9.3. Has temporary damage to hearing (e.g. punctured ear drum) 9.4. Unable to detect a 740Hz tone played at 85dB in both ears. 9.5. Implanted pacemaker or implanted electrical stimulators 9.6. Metal or plastic implants in the skull, excluding dental/facial implants 9.7. Unhealthy scalp (apparent open wounds and/or bruised or weakened skin) 9.8. Previous exposure to the NeuroCatch® Platform 2 audio sequences in the last 3 months

Study Design


Intervention

Device:
BioFlex Dualport System
The device consists of a laptop computer preprogrammed with the Bioflex® Practitioner+ Software, the Bioflex® DUO 180+ array pad that has 180 bicolour Light Emitting Diodes (LED) that emit red and near infrared light, and two laser probes, the LD-R 100 that emits red light, and the LD-I 200 that emits near infrared light.
Sham device
Control

Locations

Country Name City State
Canada Meditech Rehabilitation Centre Etobicoke Ontario
Canada Center for Neurology Studies Surrey British Columbia

Sponsors (2)

Lead Sponsor Collaborator
Dr George Medvedev MediTech International Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response size of selected ERPs (N100, P300, N400) acquired using the NeuroCatch Platform 2 Event-related potentials (ERPs) Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)
Primary Response timing of selected ERPs (N100, P300, N400) acquired using the NeuroCatch Platform 2 Event-related potentials (ERPs) Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)
Secondary Number of adverse events Frequency and severity of adverse events Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)
Secondary Number of adverse device effects Frequency and severity of adverse device effects Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)
Secondary Pain Catastrophizing Scale Score Mean, standard deviation, and assessment of variance. It is a 13-item scale, with a total range of 0 to 52. Higher scores are associated with higher amounts of pain catastrophizing. Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)
Secondary Rivermead Post-Concussion Symptoms Questionnaire Score Mean, standard deviation, and assessment of variance. Scored on a scale of 0-64 where higher scores reflect greater severity of post concussive symptoms. Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)
See also
  Status Clinical Trial Phase
Recruiting NCT04372797 - Standardized Instruments to Provide Diagnostic and Prognostic Information in Mild Traumatic Brain Injury (mTBI) N/A
Completed NCT01903525 - DHA For The Treatment of Pediatric Concussion Related to Sports Injury Phase 1
Completed NCT01847040 - Deployment Related Mild Traumatic Brain Injury (mTBI)
Completed NCT03678077 - Trends in Cohabitation Status, Academic Achievement and Socio-economic Indicators After Mild Traumatic Brain Injury
Recruiting NCT05682677 - Combined Neuromodulation and Cognitive Training for Post-mTBI Depression N/A
Terminated NCT03345550 - OPTIMA-TBI Pilot Study Phase 2
Completed NCT05095012 - RECOVER Clinical Pathway for Pediatric Concussion N/A
Recruiting NCT05886400 - The Effects of Environmental Distractions on SCAT6 Outcomes N/A
Recruiting NCT05262361 - Persistent Post-Concussion Symptoms With Convergence Insufficiency N/A
Active, not recruiting NCT03892291 - Objective Dual-task Turning Measures for Return-to-duty Assessments
Completed NCT03688984 - Treatment of Insomnia for Adolescents With Mild Traumatic Brain Injury N/A
Completed NCT02057081 - Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI N/A
Recruiting NCT06233851 - t-BIOMAP : Prospective Paediatric Cohort Study of Blood Biomarkers in mTBI
Completed NCT02844946 - One-Day Life Skills Workshop for Veterans With TBI, Pain and Psychopathology N/A
Completed NCT04641767 - BIOmarkers of TRAumatic Brain Injury Spain (BIOTRABIS)
Recruiting NCT06112093 - Repetitive Transcranial Magnetic Stimulation for Post-concussion Headaches N/A
Recruiting NCT03819608 - Neuromodulation and Neurorehabilitation for mTBI Plus PTSD N/A
Withdrawn NCT00580918 - Functional MRI Study of Attention in Normal Controls and Traumatic Brain Injured Patients
Completed NCT03319966 - Eyetracking and Neurovision Rehabilitation of Oculomotor Dysfunction in Mild Traumatic Brain Injury
Recruiting NCT03846830 - Incremental Velocity Error as a New Treatment in Vestibular Rehabilitation N/A